{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:03:17Z","timestamp":1789668197125,"version":"4.0.1"},"reference-count":344,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T00:00:00Z","timestamp":1607126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["860325"],"award-info":[{"award-number":["860325"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Pseudomonas aeruginosa is a leading cause of chronic respiratory infections in people with cystic fibrosis (CF), bronchiectasis or chronic obstructive pulmonary disease (COPD), and acute infections in immunocompromised individuals. The adaptability of this opportunistic pathogen has hampered the development of antimicrobial therapies, and consequently, it remains a major threat to public health. Due to its antimicrobial resistance, vaccines represent an alternative strategy to tackle the pathogen, yet despite over 50 years of research on anti-Pseudomonas vaccines, no vaccine has been licensed. Nevertheless, there have been many advances in this field, including a better understanding of the host immune response and the biology of P. aeruginosa. Multiple antigens and adjuvants have been investigated with varying results. Although the most effective protective response remains to be established, it is clear that a polarised Th2 response is sub-optimal, and a mixed Th1\/Th2 or Th1\/Th17 response appears beneficial. This comprehensive review collates the current understanding of the complexities of P. aeruginosa-host interactions and its implication in vaccine design, with a view to understanding the current state of Pseudomonal vaccine development and the direction of future efforts. It highlights the importance of the incorporation of appropriate adjuvants to the protective antigen to yield optimal protection.<\/jats:p>","DOI":"10.3390\/cells9122617","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T21:37:42Z","timestamp":1607377062000},"page":"2617","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Understanding Pseudomonas aeruginosa\u2013Host Interactions: The Ongoing Quest for an Efficacious Vaccine"],"prefix":"10.3390","volume":"9","author":[{"given":"Maite","family":"Sainz-Mej\u00edas","sequence":"first","affiliation":[{"name":"School of Biomolecular and Biomedical Sciences, University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5433-5389","authenticated-orcid":false,"given":"Irene","family":"Jurado-Mart\u00edn","sequence":"additional","affiliation":[{"name":"School of Biomolecular and Biomedical Sciences, University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6389-2542","authenticated-orcid":false,"given":"Siobh\u00e1n","family":"McClean","sequence":"additional","affiliation":[{"name":"School of Biomolecular and Biomedical Sciences, University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.drudis.2018.07.003","article-title":"Updates on the pathogenicity status of Pseudomonas aeruginosa","volume":"24","author":"Azam","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bianconi, I., Jeukens, J., Freschi, L., Alcal\u00e1-Franco, B., Facchini, M., Boyle, B., Molinaro, A., Kukavica-Ibrulj, I., T\u00fcmmler, B., and Levesque, R.C. (2015). Comparative genomics and biological characterization of sequential Pseudomonas aeruginosa isolates from persistent airways infection. BMC Genom., 16.","DOI":"10.1186\/s12864-015-2276-8"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"T\u00fcmmler, B. (2019). Emerging therapies against infections with Pseudomonas aeruginosa. F1000Res, 8.","DOI":"10.12688\/f1000research.19509.1"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Huang, W., Hamouche, J.E., Wang, G., Smith, M., Yin, C., Dhand, A., Dimitrova, N., and Fallon, J.T. (2020). Integrated Genome-Wide Analysis of an Isogenic Pair of Pseudomonas aeruginosa Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane\/Tazobactam, Ceftazidime\/Avibactam, and Piperacillin\/Tazobactam. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031026"},{"key":"ref_5","unstructured":"Center for Disease Control and Prevention (USA) (2020, August 10). Antibiotic Resistance Threats in the United States, Available online: https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.3389\/fimmu.2018.03021","article-title":"Genome-Based Approach Delivers Vaccine Candidates against Pseudomonas aeruginosa","volume":"9","author":"Bianconi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Horcajada, J.P., Montero, M., Oliver, A., Sorl\u00ed, L., Luque, S., G\u00f3mez-Zorrilla, S., Benito, N., and Grau, S. (2019). Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin. Microbiol. Rev., 32.","DOI":"10.1128\/CMR.00031-19"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13054-020-2792-z","article-title":"Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial","volume":"24","author":"Adlbrecht","year":"2020","journal-title":"Crit. Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/hv.34296","article-title":"Vaccination against respiratory Pseudomonas aeruginosa infection","volume":"11","author":"Grimwood","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_11","unstructured":"Marshall, B., AF, A.F., Loeffler, D., Elbert, A., O\u2019Neil, T., Rush, T., and Rizvi, S. (2018). Patient Registry Annual Data Report, Cystic Fibrosis Foundation."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1753425909106436","article-title":"Lipopolysaccharide biosynthesis in Pseudomonas aeruginosa","volume":"15","author":"King","year":"2009","journal-title":"Innate Immun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00203-014-1030-y","article-title":"Expression of the lipopolysaccharide biosynthesis gene lpxD affects biofilm formation of Pseudomonas aeruginosa","volume":"197","author":"Alshalchi","year":"2015","journal-title":"Arch. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Huszczynski, S.M., Lam, J.S., and Khursigara, C.M. (2019). The role of Pseudomonas aeruginosa lipopolysaccharide in bacterial pathogenesis and physiology. Pathogens, 9.","DOI":"10.3390\/pathogens9010006"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/femsre\/fux020","article-title":"Structure, function and regulation of Pseudomonas aeruginosa porins","volume":"41","author":"Chevalier","year":"2017","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_16","first-page":"17","article-title":"Pseudomonas chemotaxis","volume":"39","author":"Sampedro","year":"2015","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/biology2041242","article-title":"The role of the bacterial flagellum in adhesion and virulence","volume":"2","author":"Haiko","year":"2013","journal-title":"Biology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1146\/annurev-micro-092611-150055","article-title":"Pseudomonas aeruginosa twitching motility: Type IV pili in action","volume":"66","author":"Burrows","year":"2012","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4014\/jmb.1611.11056","article-title":"Pseudomonas aeruginosa biofilm, a programmed bacterial life for fitness","volume":"27","author":"Lee","year":"2017","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3389\/fmicb.2019.01582","article-title":"Can Biofilm Be Reversed through Quorum Sensing in Pseudomonas aeruginosa?","volume":"10","author":"Yan","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1574-6976.2011.00322.x","article-title":"Pseudomonas biofilm matrix composition and niche biology","volume":"36","author":"Mann","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ijmm.2010.08.005","article-title":"Protein secretion systems in Pseudomonas aeruginosa: A wealth of pathogenic weapons","volume":"300","author":"Bleves","year":"2010","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fmicb.2019.01100","article-title":"Relationship Between Quorum Sensing and Secretion Systems","volume":"10","author":"Pena","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.tips.2016.05.011","article-title":"Targeting the Type Three Secretion System in Pseudomonas aeruginosa","volume":"37","author":"Anantharajah","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3389\/fmicb.2015.00963","article-title":"Pseudomonas Exotoxin A: Optimized by evolution for effective killing","volume":"6","author":"Michalska","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hall, S., McDermott, C., Anoopkumar-Dukie, S., McFarland, A.J., Forbes, A., Perkins, A.V., Davey, A.K., Chess-Williams, R., Kiefel, M.J., and Arora, D. (2016). Cellular Effects of Pyocyanin, a Secreted Virulence Factor of Pseudomonas aeruginosa. Toxins, 8.","DOI":"10.3390\/toxins8080236"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s13213-011-0273-y","article-title":"Contribution of an arsenal of virulence factors to pathogenesis of Pseudomonas aeruginosa infections","volume":"61","author":"Strateva","year":"2011","journal-title":"Ann. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1128\/IAI.01772-05","article-title":"Rhamnolipids are virulence factors that promote early infiltration of primary human airway epithelia by Pseudomonas aeruginosa","volume":"74","author":"Zulianello","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1165\/rcmb.2008-0357OC","article-title":"Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection","volume":"42","author":"Halldorsson","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"060001","DOI":"10.1063\/1.5139147","article-title":"Quorum machinery: Effect of the Las system in Rhl regulation of P. aeruginosa","volume":"Volume 2192","author":"Alfiniyah","year":"2019","journal-title":"AIP Conference Proceedings"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00138-18","DOI":"10.1128\/CMR.00138-18","article-title":"Cystic fibrosis and Pseudomonas aeruginosa: The host-microbe interface","volume":"32","author":"Malhotra","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fcimb.2013.00075","article-title":"Pseudomonas aeruginosa adapts its iron uptake strategies in function of the type of infections","volume":"3","author":"Cornelis","year":"2013","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/cbic.201900564","article-title":"Scavenging Bacterial Siderophores with Engineered Lipocalin Proteins as an Alternative Antimicrobial Strategy","volume":"21","author":"Dauner","year":"2020","journal-title":"ChemBioChem"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13238-014-0100-x","article-title":"The hierarchy quorum sensing network in Pseudomonas aeruginosa","volume":"6","author":"Lee","year":"2015","journal-title":"Protein Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/2049-632X.12033","article-title":"Pseudomonas aeruginosa: New insights into pathogenesis and host defenses","volume":"67","author":"Gellatly","year":"2013","journal-title":"Pathog. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/thoraxjnl-2015-207588","article-title":"Airway surface liquid homeostasis in cystic fibrosis: Pathophysiology and therapeutic targets","volume":"71","author":"Haq","year":"2016","journal-title":"Thorax"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.tim.2016.01.008","article-title":"Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections","volume":"24","author":"Winstanley","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/pathogens4010066","article-title":"Bacterial Adaptation during Chronic Respiratory Infections","volume":"4","author":"Cullen","year":"2015","journal-title":"Pathogens"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nrmicro2907","article-title":"Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: An evolutionary perspective","volume":"10","author":"Folkesson","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00966-14","DOI":"10.1128\/mBio.00966-14","article-title":"Within-host evolution of Pseudomonas aeruginosa reveals adaptation toward iron acquisition from hemoglobin","volume":"5","author":"Marvig","year":"2014","journal-title":"mBio"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1099\/mic.0.000155","article-title":"Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: Strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains","volume":"161","author":"Cullen","year":"2015","journal-title":"Microbiology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.3389\/fmicb.2018.03242","article-title":"Persistence and m icroevolution of Pseudomonas aeruginosa  in the cystic fibrosis lung: A single-patient longitudinal genomic study","volume":"9","author":"Bianconi","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/gene.2011.5","article-title":"Cystic fibrosis modifier genes related to Pseudomonas aeruginosa infection","volume":"12","author":"Park","year":"2011","journal-title":"Genes Immun."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Emond, M.J., Louie, T., Emerson, J., Chong, J.X., Mathias, R.A., Knowles, M.R., Rieder, M.J., Tabor, H.K., Nickerson, D.A., and Barnes, K.C. (2015). Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. PLoS Genet., 11.","DOI":"10.1371\/journal.pgen.1005424"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Di Paola, M., Park, A.J., Ahmadi, S., Roach, E.J., Wu, Y.S., Struder-Kypke, M., Lam, J.S., Bear, C.E., and Khursigara, C.M. (2017). SLC6A14 Is a Genetic Modifier of Cystic Fibrosis That Regulates Pseudomonas aeruginosa Attachment to Human Bronchial Epithelial Cells. mBio, 8.","DOI":"10.1128\/mBio.02073-17"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1038\/s41598-020-62747-9","article-title":"TAS2R38 is a novel modifier gene in patients with cystic fibrosis","volume":"10","author":"Castaldo","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1189\/jlb.0811410","article-title":"Toll-like receptors in the host defense against Pseudomonas aeruginosa respiratory infection and cystic fibrosis","volume":"92","author":"McIsaac","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"L591","DOI":"10.1152\/ajplung.00335.2013","article-title":"Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa","volume":"306","author":"Lovewell","year":"2014","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000455857","article-title":"Inflammation: A Double-Edged Sword in the Response to Pseudomonas aeruginosa Infection","volume":"9","author":"Lin","year":"2017","journal-title":"J. Innate Immun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.4049\/jimmunol.175.6.3927","article-title":"TLRs 2 and 4 are not involved in hypersusceptibility to acute Pseudomonas aeruginosa lung infections","volume":"175","author":"Ramphal","year":"2005","journal-title":"J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"L312","DOI":"10.1152\/ajplung.00250.2006","article-title":"Redundant Toll-like receptor signaling in the pulmonary host response to Pseudomonas aeruginosa","volume":"292","author":"Skerrett","year":"2007","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/infdis\/jis438","article-title":"Toll-like receptor 2 deficiency increases resistance to Pseudomonas aeruginosa pneumonia in the setting of sepsis-induced immune dysfunction","volume":"206","author":"Grimaldi","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Benmohamed, F., Medina, M., Wu, Y.Z., Maschalidi, S., Jouvion, G., Guillemot, L., Chignard, M., Manoury, B., and Touqui, L. (2014). Toll-like receptor 9 deficiency protects mice against Pseudomonas aeruginosa lung infection. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090466"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"L1112","DOI":"10.1152\/ajplung.00155.2009","article-title":"Role of Toll-like receptor 5 in the innate immune response to acute P. aeruginosa pneumonia","volume":"297","author":"Morris","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1002\/eji.201040421","article-title":"TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin","volume":"40","author":"Carvalho","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fcimb.2017.00130","article-title":"Signaling Mediated by Toll-l ike receptor 5 sensing of Pseudomonas aeruginosa flagellin influences IL-1 \u03b2 and IL-18 production by primary fibroblasts derived from the human cornea","volume":"7","author":"Cendra","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"101373","DOI":"10.1016\/j.cimid.2019.101373","article-title":"The Pseudomonas aeruginosa HSP70-like protein DnaK induces IL-1\u03b2 expression via TLR4-dependent activation of the NF-\u03baB and JNK signaling pathways","volume":"67","author":"Lee","year":"2019","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000367790","article-title":"Redundant and cooperative interactions between TLR5 and NLRC4 in protective lung mucosal immunity against Pseudomonas aeruginosa","volume":"7","author":"Tolle","year":"2015","journal-title":"J. Innate Immun."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Dosunmu, E.F., Emeh, R.O., Dixit, S., Bakeer, M.K., Coats, M.T., Owen, D.R., Pillai, S.R., Singh, S.R., and Dennis, V.A. (2017). The anti-microbial peptide TP359 attenuates inflammation in human lung cells infected with Pseudomonas aeruginosa via TLR5 and MAPK pathways. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176640"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Pang, Z., Junkins, R.D., Raudonis, R., MacNeil, A.J., McCormick, C., Cheng, Z., and Lin, T.J. (2018). Regulator of calcineurin 1 differentially regulates TLR-dependent MyD88 and TRIF signaling pathways. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197491"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1128\/IAI.01384-15","article-title":"Toll-Like Receptor 4 Agonistic Antibody Promotes Host Defense against Chronic Pseudomonas aeruginosa Lung Infection in Mice","volume":"84","author":"Nakamura","year":"2016","journal-title":"Infect. Immun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.micinf.2011.07.011","article-title":"Innate immune responses to Pseudomonas aeruginosa infection","volume":"13","author":"Lavoie","year":"2011","journal-title":"Microbes Infect."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.4049\/jimmunol.1003687","article-title":"Airway epithelial MyD88 restores control of Pseudomonas aeruginosa murine infection via an IL-1-dependent pathway","volume":"186","author":"Mijares","year":"2011","journal-title":"J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e50458","DOI":"10.7554\/eLife.50458","article-title":"TLR5 participates in the TLR4 receptor complex and promotes MyD88-dependent signaling in environmental lung injury","volume":"9","author":"Hussain","year":"2020","journal-title":"Elife"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00011-018-1132-0","article-title":"NOD-like receptor(s) and host immune responses with Pseudomonas aeruginosa infection","volume":"67","author":"Alhazmi","year":"2018","journal-title":"Inflamm. Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"McHugh, B.J., Wang, R., Li, H.N., Beaumont, P.E., Kells, R., Stevens, H., Young, L., Rossi, A.G., Gray, R.D., and Dorin, J.R. (2019). Cathelicidin is a \u201cfire alarm\u201d, generating protective NLRP3-dependent airway epithelial cell inflammatory responses during infection with Pseudomonas aeruginosa. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007694"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1159\/000446840","article-title":"Current Concepts and Controversies in Innate Immunity of Cystic Fibrosis Lung Disease","volume":"8","author":"Ralhan","year":"2016","journal-title":"J. Innate Immun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.4049\/jimmunol.1501642","article-title":"Clinical Isolates of Pseudomonas aeruginosa from Chronically Infected Cystic Fibrosis Patients Fail to Activate the Inflammasome during Both Stable Infection and Pulmonary Exacerbation","volume":"196","author":"Huus","year":"2016","journal-title":"J. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/imcb.12190","article-title":"Membrane vesicles from Pseudomonas aeruginosa activate the noncanonical inflammasome through caspase-5 in human monocytes","volume":"96","author":"Bitto","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1128\/IAI.00144-10","article-title":"Pseudomonas aeruginosa evasion of phagocytosis is mediated by loss of swimming motility and is independent of flagellum expression","volume":"78","author":"Amiel","year":"2010","journal-title":"Infect. Immun."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Rada, B. (2017). Interactions between Neutrophils and Pseudomonas aeruginosa in Cystic Fibrosis. Pathogens, 6.","DOI":"10.3390\/pathogens6010010"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Geddes-McAlister, J., Kugadas, A., and Gadjeva, M. (2019). Tasked with a Challenging Objective: Why Do Neutrophils Fail to Battle Pseudomonas aeruginosa biofilms. Pathogens, 8.","DOI":"10.3390\/pathogens8040283"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Giacalone, V.D., Margaroli, C., Mall, M.A., and Tirouvanziam, R. (2020). Neutrophil Adaptations upon Recruitment to the Lung: New Concepts and Implications for Homeostasis and Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030851"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3389\/fimmu.2020.00595","article-title":"Progress in Model Systems of Cystic Fibrosis Mucosal Inflammation to Understand Aberrant Neutrophil Activity","volume":"11","author":"Laucirica","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"L198","DOI":"10.1152\/ajplung.90472.2008","article-title":"Depletion of phagocytes in the reticuloendothelial system causes increased inflammation and mortality in rabbits with Pseudomonas aeruginosa pneumonia","volume":"296","author":"Kurahashi","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1128\/IAI.01969-14","article-title":"Polymorphonuclear leukocytes restrict growth of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients","volume":"82","author":"Kragh","year":"2014","journal-title":"Infect. Immun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000444125","article-title":"CXCR1 Regulates Pulmonary Anti-Pseudomonas Host Defense","volume":"8","author":"Carevic","year":"2016","journal-title":"J. Innate Immun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1128\/IAI.68.7.4289-4296.2000","article-title":"CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia","volume":"68","author":"Tsai","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1189\/jlb.0806502","article-title":"CXCL1\/KC and CXCL5\/LIX are selectively produced by corneal fibroblasts and mediate neutrophil infiltration to the corneal stroma in LPS keratitis","volume":"81","author":"Lin","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2174\/1389450117666151209120516","article-title":"Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target","volume":"17","author":"Guan","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3389\/fimmu.2019.01670","article-title":"Regulation of Pseudomonas aeruginosa-Mediated Neutrophil Extracellular Traps","volume":"10","author":"Theprungsirikul","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e00814-18","DOI":"10.1128\/IAI.00814-18","article-title":"Gamma Interferon and Interleukin-17A Differentially Influence the Response of Human Macrophages and Neutrophils to Pseudomonas aeruginosa Infection","volume":"87","author":"Muntaka","year":"2019","journal-title":"Infect. Immun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e00171-20","DOI":"10.1128\/IAI.00171-20","article-title":"Mice Lacking \u03b3\u03b4 T Cells Exhibit Impaired Clearance of Pseudomonas aeruginosa Lung Infection and Excessive Production of Inflammatory Cytokines","volume":"88","author":"Omar","year":"2020","journal-title":"Infect. Immun."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Garai, P., Berry, L., Moussouni, M., Bleves, S., and Blanc-Potard, A.B. (2019). Killing from the inside: Intracellular role of T3SS in the fate of Pseudomonas aeruginosa within macrophages revealed by mgtC and oprF mutants. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007812"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1128\/IAI.00081-15","article-title":"Identification of OprF as a complement component C3 binding acceptor molecule on the surface of Pseudomonas aeruginosa","volume":"83","author":"Mishra","year":"2015","journal-title":"Infect. Immun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcf.2017.08.012","article-title":"Mechanisms of humoral immune response against Pseudomonas aeruginosa biofilm infection in cystic fibrosis","volume":"17","author":"Mauch","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1046\/j.1365-2249.1996.d01-618.x","article-title":"Interferon-gamma (IFN-gamma) treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats","volume":"103","author":"Johansen","year":"1996","journal-title":"Clin. Exp. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Singh, S., Barr, H., Liu, Y.C., Robins, A., Heeb, S., Williams, P., Fogarty, A., C\u00e1mara, M., and Mart\u00ednez-Pomares, L. (2015). Granulocyte-macrophage colony stimulatory factor enhances the pro-inflammatory response of interferon-\u03b3-treated macrophages to Pseudomonas aeruginosa infection. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117447"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41385-020-0270-1","article-title":"Host responses to mucosal biofilms in the lung and gut","volume":"13","author":"Domingue","year":"2020","journal-title":"Mucosal. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1513\/AnnalsATS.201711-868MG","article-title":"Interleukin-13 Stimulation Reveals the Cellular and Functional Plasticity of the Airway Epithelium","volume":"15","author":"Seibold","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/21645515.2019.1650999","article-title":"Immunological considerations in the development of Pseudomonas aeruginosa vaccines","volume":"16","author":"Baker","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1164\/rccm.201202-0182OC","article-title":"Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia","volume":"186","author":"Wu","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1348-0421.12467","article-title":"Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia","volume":"61","author":"Hamaoka","year":"2017","journal-title":"Microbiol. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1016\/j.vaccine.2018.10.010","article-title":"PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia","volume":"36","author":"Schaefers","year":"2018","journal-title":"Vaccine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.vaccine.2018.12.053","article-title":"Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia","volume":"37","author":"Baker","year":"2019","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.immuni.2011.10.018","article-title":"Th17 cells mediate clade-specific, serotype-independent mucosal immunity","volume":"35","author":"Chen","year":"2011","journal-title":"Immunity"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"986789","DOI":"10.1155\/2013\/986789","article-title":"Th17 cells in immunity and autoimmunity","volume":"2013","author":"Bedoya","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1128\/IAI.00717-16","article-title":"Interleukin-17 Is Required for Control of Chronic Lung Infection Caused by Pseudomonas aeruginosa","volume":"84","author":"Bayes","year":"2016","journal-title":"Infect. Immun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.13006","article-title":"Updates on T helper type 17 immunity in respiratory disease","volume":"156","author":"Iwanaga","year":"2019","journal-title":"Immunology"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Neill, D.R., Saint, G.L., Bricio-Moreno, L., Fothergill, J.L., Southern, K.W., Winstanley, C., Christmas, S.E., Slupsky, J.R., McNamara, P.S., and Kadioglu, A. (2014). The B lymphocyte differentiation factor (BAFF) is expressed in the airways of children with CF and in lungs of mice infected with Pseudomonas aeruginosa. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095892"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fcimb.2016.00170","article-title":"IL17-Producing \u03b3\u03b4 T Cells May Enhance Humoral Immunity during Pulmonary Pseudomonas aeruginosa infection in mice","volume":"6","author":"Pan","year":"2016","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcf.2017.09.004","article-title":"IgG avidity to Pseudomonas aeruginosa over the course of chronic lung biofilm infection in cystic fibrosis","volume":"17","author":"Mauch","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_103","first-page":"2032057","article-title":"The Effects of Secretory IgA in the Mucosal Immune System","volume":"2020","author":"Li","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1569-1993(13)00150-1","article-title":"Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis","volume":"12","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00430-019-00578-w","article-title":"Secretory IgA-mediated immune response in saliva and early detection of Pseudomonas aeruginosa in the lower airways of pediatric cystic fibrosis patients","volume":"208","author":"Mauch","year":"2019","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12931-018-0750-y","article-title":"Airway disease phenotypes in animal models of cystic fibrosis","volume":"19","author":"McCarron","year":"2018","journal-title":"Respir. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1089\/hum.2020.013","article-title":"Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease","volume":"31","author":"Tang","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3389\/fphar.2018.01475","article-title":"Animal Models in the Pathophysiology of Cystic Fibrosis","volume":"9","author":"Semaniakou","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"21465","DOI":"10.1038\/srep21465","article-title":"Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections","volume":"6","author":"Cigana","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/978-1-4939-0473-0_58","article-title":"Assessing Pseudomonas aeruginosa virulence and the host response using murine models of acute and chronic lung infection","volume":"1149","author":"Facchini","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2217\/fmb.12.106","article-title":"40 years on: Have we finally got a vaccine for Pseudomonas aeruginosa?","volume":"7","author":"Worgall","year":"2012","journal-title":"Future Microbiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1099\/00222615-10-1-19","article-title":"A new polyvalent Pseudomonas vaccine","volume":"10","author":"Miler","year":"1977","journal-title":"J. Med. Microbiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/iai.52.1.161-165.1986","article-title":"Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine","volume":"52","author":"Cryz","year":"1986","journal-title":"Infect. Immun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1574-695X.2006.00103.x","article-title":"Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis","volume":"47","author":"Zuercher","year":"2006","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2249.2005.02964.x","article-title":"Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine","volume":"143","author":"Zuercher","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1128\/IAI.68.11.6202-6208.2000","article-title":"Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine","volume":"68","author":"McIntosh","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/infdis\/151.4.581","article-title":"Studies on the ability of alginate to act as a protective immunogen against infection with Pseudomonas aeruginosa in animals","volume":"151","author":"Woods","year":"1985","journal-title":"J. Infect. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"S426","DOI":"10.1093\/clinids\/8.Supplement_4.S426","article-title":"Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia","volume":"8","author":"Pennington","year":"1986","journal-title":"Rev. Infect. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1126\/science.2116663","article-title":"Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections","volume":"249","author":"Pier","year":"1990","journal-title":"Science"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1128\/iai.59.1.45-50.1991","article-title":"Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine","volume":"59","author":"Cryz","year":"1991","journal-title":"Infect. Immun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1128\/IAI.71.7.3875-3884.2003","article-title":"Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine","volume":"71","author":"Theilacker","year":"2003","journal-title":"Infect. Immun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1128\/iai.35.1.276-280.1982","article-title":"Flagellar preparations from Pseudomonas aeruginosa: Animal protection studies","volume":"35","author":"Holder","year":"1982","journal-title":"Infect. Immun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005373-198602000-00003","article-title":"Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Immunization using divalent flagella preparations","volume":"26","author":"Holder","year":"1986","journal-title":"J. Trauma"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1128\/IAI.00806-09","article-title":"Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines","volume":"78","author":"Llosa","year":"2010","journal-title":"Infect. Immun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e6760","DOI":"10.5812\/jjm.6760","article-title":"Pseudomonas aeruginosa recombinant flagellin induced poly-isotypic humoral immune responses in the Balb\/C mice","volume":"6","author":"Shajiei","year":"2013","journal-title":"Jundishapur J. Microbiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/apm.12101","article-title":"Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection","volume":"122","author":"Faezi","year":"2014","journal-title":"APMIS"},{"key":"ref_127","first-page":"30026","article-title":"Immunogenicity of Pseudomonas aeruginosa recombinant b-type fagellin as a vaccine candidate: Protective efficacy in a murine burn wound sepsis model","volume":"16","author":"Behrouz","year":"2016","journal-title":"Burns"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.molimm.2016.04.008","article-title":"Immunogenicity and protective efficacy of Pseudomonas aeruginosa type a and b flagellin vaccines in a burned mouse model","volume":"74","author":"Laghaei","year":"2016","journal-title":"Mol. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1128\/IAI.00157-11","article-title":"Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice","volume":"79","author":"Llosa","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.biologicals.2017.04.001","article-title":"Preparation of Pseudomonas aeruginosa alginate-flagellin immunoconjugate","volume":"47","author":"Faezi","year":"2017","journal-title":"Biologicals"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1139\/cjm-2014-0501","article-title":"Protective efficacy of recombinant exotoxin A-flagellin fusion protein against Pseudomonas aeruginosa infection","volume":"61","author":"Farajnia","year":"2015","journal-title":"Can. J. Microbiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/IAI.00054-09","article-title":"A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of non-mucoid Pseudomonas aeruginosa","volume":"77","author":"Weimer","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1016\/j.vaccine.2009.08.080","article-title":"Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa","volume":"27","author":"Weimer","year":"2009","journal-title":"Vaccine"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jmii.2016.08.014","article-title":"Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa","volume":"51","author":"Hassan","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0264-410X(00)00362-5","article-title":"Expression and testing of Pseudomonas aeruginosa vaccine candidate proteins prepared with the Caulobacter crescentus S-layer protein expression system","volume":"19","author":"Nomellini","year":"2001","journal-title":"Vaccine"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1574-695X.2006.00069.x","article-title":"Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice","volume":"47","author":"Ohama","year":"2006","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.biologicals.2016.06.009","article-title":"Protective effect of pilin protein with alum+naloxone adjuvant against acute pulmonary Pseudomonas aeruginosa infection","volume":"44","author":"Banadkoki","year":"2016","journal-title":"Biologicals"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1128\/IAI.69.11.6962-6969.2001","article-title":"Dual-function vaccine for Pseudomonas aeruginosa: Characterization of chimeric exotoxin A-pilin protein","volume":"69","author":"Hertle","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1128\/IAI.73.11.7705-7717.2005","article-title":"Intranasal immunization strategy to impede pilin-mediated binding of Pseudomonas aeruginosa to airway epithelial cells","volume":"73","author":"Hsieh","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.imlet.2016.04.002","article-title":"Flagellin and pilin immunization against multi-drug resistant Pseudomonas aeruginosa protects mice in the burn wound sepsis model","volume":"176","author":"Korpi","year":"2016","journal-title":"Immunol. Lett."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"103697","DOI":"10.1016\/j.micpath.2019.103697","article-title":"A trivalent vaccine consisting of \u201cflagellin A+B and pilin\u201d protects against Pseudomonas aeruginosa infection in a murine burn model","volume":"138","author":"Hashemi","year":"2020","journal-title":"Microb. Pathog."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/lam.12796","article-title":"Immunogenicity of a fusion protein containing PilQ and disulphide turn region of PilA from Pseudomonas aeruginosa in mice","volume":"65","author":"Gholami","year":"2017","journal-title":"Lett. Appl. Microbiol."},{"key":"ref_143","first-page":"38","article-title":"Induction of Specific Humoral Immune Response in Mice against a Pseudomonas aeruginosa chimeric PilQ\/PilA protein","volume":"7","author":"Gholami","year":"2018","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CVI.00476-07","article-title":"Immunization with a Pseudomonas aeruginosa 1244 pilin provides O-antigen-specific protection","volume":"15","author":"Horzempa","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1399-3011.1998.tb01243.x","article-title":"The use of synthetic peptides in the design of a consensus sequence vaccine for Pseudomonas aeruginosa","volume":"52","author":"Cachia","year":"1998","journal-title":"J. Pept. Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jmb.2007.09.032","article-title":"Animal protection and structural studies of a consensus sequence vaccine targeting the receptor binding domain of the type IV pilus of Pseudomonas aeruginosa","volume":"374","author":"Kao","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molimm.2020.05.009","article-title":"Immunopotentiation of the engineered low-molecular-weight pilin targeting Pseudomonas aeruginosa: A combination of immunoinformatics investigation and active immunization","volume":"124","author":"Ahmadbeigi","year":"2020","journal-title":"Mol. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1128\/iai.58.7.2241-2244.1990","article-title":"Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli","volume":"58","author":"Finke","year":"1990","journal-title":"Infect. Immun."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1128\/iai.59.4.1251-1254.1991","article-title":"Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies","volume":"59","author":"Finke","year":"1991","journal-title":"Infect. Immun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF02091993","article-title":"Pseudomonas aeruginosa outer membrane protein F produced in Escherichia coli retains vaccine efficacy","volume":"20","author":"Robertson","year":"1990","journal-title":"Curr. Microbiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-1656(00)00311-4","article-title":"Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections","volume":"83","author":"Gabelsberger","year":"2000","journal-title":"J. Biotechnol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijbiomac.2020.05.057","article-title":"Oligomerization of IC43 resulted in improved immunogenicity and protective efficacy against Pseudomonas aeruginosa lung infection","volume":"159","author":"Jing","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00253-014-6147-z","article-title":"Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity","volume":"99","author":"Cui","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"151415","DOI":"10.1016\/j.ijmm.2020.151415","article-title":"Recombinant N-terminal outer membrane porin (OprF) of Pseudomonas aeruginosa is a promising vaccine candidate against both P. aeruginosa and some strains of Acinetobacter baumannii","volume":"310","author":"Mohamed","year":"2020","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s002530051555","article-title":"Recombinant protein composed of Pseudomonas exotoxin A, outer membrane proteins I and F as vaccine against P. aeruginosa infection","volume":"52","author":"Chen","year":"1999","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1099\/00222615-38-2-79","article-title":"Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model","volume":"38","author":"Gilleland","year":"1993","journal-title":"J. Med. Microbiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2147\/IDR.S244081","article-title":"Protective Efficacy of the OprF\/OprI\/PcrV Recombinant Chimeric Protein Against Pseudomonas aeruginosa","volume":"13","author":"Fakoor","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"41607","DOI":"10.1038\/srep41607","article-title":"Bioengineering a bacterial pathogen to assemble its own particulate vaccine capable of inducing cellular immunity","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40011-015-0580-3","article-title":"Over-Expression and Immunogenicity of Outer Membrane Protein L (OprL) of Pseudomonas aeruginosa","volume":"87","author":"Ingle","year":"2015","journal-title":"Proc. Natl. Acad. Sci. India Sect. B Biol. Sci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.clim.2017.09.022","article-title":"Vaccination with a recombinant OprL fragment induces a Th17 response and confers serotype-independent protection against Pseudomonas aeruginosa infection in mice","volume":"183","author":"Gao","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3389\/fimmu.2018.01737","article-title":"Construction of a Protective Vaccine against Lipopolysaccharide-Heterologous Pseudomonas aeruginosa strains based on expression profiling of outer membrane proteins during infection","volume":"9","author":"Liu","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/7391","article-title":"Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury","volume":"5","author":"Sawa","year":"1999","journal-title":"Nat. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/1348-0421.12658","article-title":"The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia","volume":"62","author":"Naito","year":"2018","journal-title":"Microbiol. Immunol."},{"key":"ref_164","first-page":"121","article-title":"In-Silico Analysis and Protective Efficacy of the PcrV Recombinant Vaccine against Pseudomonas aeruginosa in the Burned and PA-Infected BALB\/c Mouse Model","volume":"17","author":"Fakoor","year":"2020","journal-title":"Iran. J. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1348-0421.2009.00165.x","article-title":"Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice","volume":"53","author":"Moriyama","year":"2009","journal-title":"Microbiol. Immunol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fimmu.2019.00781","article-title":"Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine against Pseudomonas aeruginosa","volume":"10","author":"Wan","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_167","first-page":"15","article-title":"Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa","volume":"15","author":"Golpasha","year":"2015","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/s41598-017-04029-5","article-title":"Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1128\/iai.56.12.3095-3098.1988","article-title":"Toxoid of Pseudomonas aeruginosa exotoxin A generated by deletion of an active-site residue","volume":"56","author":"Lukac","year":"1988","journal-title":"Infect. Immun."},{"key":"ref_170","first-page":"357","article-title":"A nontoxic Pseudomonas exotoxin A induces active immunity and passive protective antibody against Pseudomonas exotoxin A intoxication","volume":"6","author":"Chen","year":"1999","journal-title":"J. Biomed. Sci."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5812\/ijb.10149","article-title":"Protective Properties of Nontoxic Recombinant Exotoxin A (Domain I-II) against Pseudomonas aeruginosa Infection","volume":"11","author":"Tanomand","year":"2013","journal-title":"Iran. J. Biotechnol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11274-019-2669-y","article-title":"Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: Protectivity in murine model","volume":"35","author":"Shapouri","year":"2019","journal-title":"World J. Microbiol. Biotechnol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1128\/iai.61.4.1400-1405.1993","article-title":"Site-directed mutagenesis of Glu-141 and His-223 in Pseudomonas aeruginosa elastase: Catalytic activity, processing, and protective activity of the elastase against Pseudomonas infection","volume":"61","author":"Kawamoto","year":"1993","journal-title":"Infect. Immun."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1086\/315470","article-title":"Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa or Burkholderia cepacia","volume":"81","author":"Sokol","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0264-410X(00)00146-8","article-title":"Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung","volume":"19","author":"Thomas","year":"2000","journal-title":"Vaccine"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0928-8244(03)00073-7","article-title":"Immunisation with non-integral OMPs promotes pulmonary clearance of Pseudomonas aeruginosa","volume":"37","author":"Thomas","year":"2003","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1016\/j.vaccine.2009.01.085","article-title":"Immune response mechanisms against Pseudomonas aeruginosa associated with mucosal immunization with protein antigens in a rat model of acute lung infection","volume":"27","author":"Thomas","year":"2009","journal-title":"Vaccine"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1099\/jmm.0.46658-0","article-title":"Immunization with 3-oxododecanoyl-L-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection","volume":"55","author":"Miyairi","year":"2006","journal-title":"J. Med. Microbiol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.3389\/fimmu.2019.02497","article-title":"Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice from Pseudomonas aeruginosa Acute Murine Pneumonia","volume":"10","author":"Blackwood","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.micpath.2019.04.014","article-title":"Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model","volume":"131","author":"Elhosary","year":"2019","journal-title":"Microb. Pathog."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1128\/iai.61.2.671-679.1993","article-title":"Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: Role of neutrophils and leukotriene B4","volume":"61","author":"Buret","year":"1993","journal-title":"Infect. Immun."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1128\/iai.62.12.5335-5343.1994","article-title":"Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha","volume":"62","author":"Buret","year":"1994","journal-title":"Infect. Immun."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1128\/iai.62.4.1427-1436.1994","article-title":"Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats","volume":"62","author":"Cripps","year":"1994","journal-title":"Infect. Immun."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.intimp.2019.01.055","article-title":"Hydrogen peroxide-inactivated bacteria induces potent humoral and cellular immune responses and releases nucleic acids","volume":"69","author":"Fan","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.vaccine.2018.02.040","article-title":"Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections","volume":"36","author":"Meynet","year":"2018","journal-title":"Vaccine"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1128\/IAI.70.3.1507-1517.2002","article-title":"Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine","volume":"70","author":"Priebe","year":"2002","journal-title":"Infect. Immun."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1128\/IAI.71.3.1453-1461.2003","article-title":"Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant","volume":"71","author":"Priebe","year":"2003","journal-title":"Infect. Immun."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.4049\/jimmunol.181.7.4965","article-title":"IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa","volume":"181","author":"Priebe","year":"2008","journal-title":"J. Immunol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/IAI.01139-10","article-title":"Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection","volume":"79","author":"Kamei","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Cabral, M.P., Correia, A., Vilanova, M., G\u00e4rtner, F., Moscoso, M., Garc\u00eda, P., Vallejo, J.A., P\u00e9rez, A., Francisco-Tom\u00e9, M., and Fuentes-Valverde, V. (2020). A live auxotrophic vaccine confers mucosal immunity and protection against lethal pneumonia caused by Pseudomonas aeruginosa. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008311"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4049\/jimmunol.179.2.1147","article-title":"Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine","volume":"179","author":"Saha","year":"2007","journal-title":"J. Immunol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1128\/IAI.69.5.3510-3515.2001","article-title":"Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa","volume":"69","author":"Price","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1574-695X.2002.tb00577.x","article-title":"Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa","volume":"33","author":"Price","year":"2002","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0928-8244(03)00075-0","article-title":"DNA vaccines against chronic lung infections by Pseudomonas aeruginosa","volume":"37","author":"Staczek","year":"2003","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.3382\/ps\/pey307","article-title":"Immune efficacy of DNA vaccines based on oprL and oprF genes of Pseudomonas aeruginosa in chickens","volume":"97","author":"Gong","year":"2018","journal-title":"Poult. Sci."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1016\/j.vaccine.2016.07.017","article-title":"A DNA vaccine encoding VP22 of herpes simplex virus type I (HSV-1) and OprF confers enhanced protection from Pseudomonas aeruginosa in mice","volume":"34","author":"Yu","year":"2016","journal-title":"Vaccine"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1016\/j.vaccine.2006.05.077","article-title":"Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa","volume":"24","author":"Saha","year":"2006","journal-title":"Vaccine"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1093\/infdis\/130.Supplement.S159","article-title":"Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis","volume":"130","author":"Pennington","year":"1974","journal-title":"J. Infect. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0002-9343(75)90498-2","article-title":"Use of a Pseudomonas aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis","volume":"58","author":"Pennington","year":"1975","journal-title":"Am. J. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1017\/S0022172400055364","article-title":"A new Pseudomonas vaccine: Preliminary trial on human volunteers","volume":"76","author":"Jones","year":"1976","journal-title":"J. Hyg. (Lond.)"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/adc.59.12.1131","article-title":"Prospective, controlled study of a polyvalent Pseudomonas vaccine in cystic fibrosis-three year results","volume":"59","author":"Langford","year":"1984","journal-title":"Arch. Dis. Child."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000414350","article-title":"A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine","volume":"39","author":"Cryz","year":"1987","journal-title":"Antibiot. Chemother. (1971)"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000417618","article-title":"Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans","volume":"42","author":"Cryz","year":"1989","journal-title":"Antibiot. Chemother. (1971)"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/01.inf.0000129688.50588.ac","article-title":"Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection","volume":"23","author":"Lang","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ijmm.2010.08.010","article-title":"Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"300","year":"2010","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1128\/iai.62.9.3972-3979.1994","article-title":"Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine","volume":"62","author":"Pier","year":"1994","journal-title":"Infect. Immun."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000420309","article-title":"The first clinical trial of immuno\u2019s experimental Pseudomonas aeruginosa flagellar vaccines","volume":"44","author":"Crowe","year":"1991","journal-title":"Antibiot. Chemother. (1971)"},{"key":"ref_208","first-page":"983","article-title":"Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals","volume":"151","author":"Pfeiffer","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"11020","DOI":"10.1073\/pnas.0702403104","article-title":"A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients","volume":"104","author":"Meisner","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0264-410X(98)00159-5","article-title":"Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine","volume":"17","author":"Jang","year":"1999","journal-title":"Vaccine"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0264-410X(99)00479-X","article-title":"Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy","volume":"18","author":"Lee","year":"2000","journal-title":"Vaccine"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0264-410X(00)00235-8","article-title":"Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients","volume":"19","author":"Kim","year":"2000","journal-title":"Vaccine"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0168-1656(95)00161-1","article-title":"Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates","volume":"44","author":"Knapp","year":"1996","journal-title":"J. Biotechnol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1128\/IAI.67.3.1461-1470.1999","article-title":"Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers","volume":"67","author":"Mansouri","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0928-8244(03)00072-5","article-title":"Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients","volume":"37","author":"Mansouri","year":"2003","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/hv.26565","article-title":"A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF\/I vaccine (IC43) in healthy volunteers","volume":"10","author":"Westritschnig","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13054-017-1601-9","article-title":"A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients","volume":"21","author":"Rello","year":"2017","journal-title":"Crit. Care"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/S0264-410X(00)00550-8","article-title":"Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers","volume":"19","author":"Larbig","year":"2001","journal-title":"Vaccine"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1465-9921-8-57","article-title":"Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: A clinical phase I\/II study","volume":"8","author":"Baumann","year":"2007","journal-title":"Respir. Res."},{"key":"ref_220","first-page":"262","article-title":"Vaccine strategies against Pseudomonas aeruginosa infection in the lung","volume":"98","author":"Cripps","year":"1997","journal-title":"Behring Inst. Mitt."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1128\/IAI.74.2.968-974.2006","article-title":"Safety and immunogenicity of an oral inactivated whole-cell Pseudomonas aeruginosa vaccine administered to healthy human subjects","volume":"74","author":"Cripps","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/newbio229209a0","article-title":"Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine","volume":"229","author":"Hanessian","year":"1971","journal-title":"Nat. New Biol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"518","DOI":"10.7326\/0003-4819-79-4-518","article-title":"Pseudomonas aeruginosa vaccine in cancer patients","volume":"79","author":"Young","year":"1973","journal-title":"Ann. Intern. Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1093\/infdis\/130.Supplement.S152","article-title":"Immunization against Pseudomonas in infection after thermal injury","volume":"130","author":"Wesley","year":"1974","journal-title":"J. Infect. Dis."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1128\/iai.51.2.675-686.1986","article-title":"Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV","volume":"51","author":"MacIntyre","year":"1986","journal-title":"Infect. Immun."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/09680519020080010401","article-title":"The biological activity of a liposomal complete core lipopolysaccharide vaccine","volume":"8","author":"Erridge","year":"2002","journal-title":"J. Endotoxin Res."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/infdis\/145.2.217","article-title":"Lipopolysaccharide and high-molecular-weight polysaccharide serotypes of Pseudomonas aeruginosa","volume":"145","author":"Pier","year":"1982","journal-title":"J. Infect. Dis."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1172\/JCI110453","article-title":"Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa","volume":"69","author":"Pier","year":"1982","journal-title":"J. Clin. Invest."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1128\/IAI.66.8.3719-3726.1998","article-title":"Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains","volume":"66","author":"Hatano","year":"1998","journal-title":"Infect. Immun."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1172\/JCI113062","article-title":"Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans","volume":"80","author":"Cryz","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/0140-6736(91)92103-9","article-title":"Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis","volume":"338","author":"Schaad","year":"1991","journal-title":"Lancet"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/infdis\/169.5.1159","article-title":"Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa","volume":"169","author":"Cryz","year":"1994","journal-title":"J. Infect. Dis."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0022-3476(95)70158-3","article-title":"Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"127","author":"Lang","year":"1995","journal-title":"J. Pediatr."},{"key":"ref_234","first-page":"345","article-title":"Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine","volume":"98","author":"Cryz","year":"1997","journal-title":"Behring Inst. Mitt."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s11274-007-9399-2","article-title":"LPS-based conjugate vaccines composed of O-polysaccharide from Pseudomonas aeruginosa IATS 6 and 11 bound to a carrier protein","volume":"23","author":"Masoud","year":"2007","journal-title":"World J. Microbiol. Biotechnol."},{"key":"ref_236","first-page":"1565","article-title":"Preparation and immune characteristics of Pseudomonas aeruginosa-IATS 3 O-specific polysaccharide-tetanus toxoid conjugate","volume":"25","author":"Xie","year":"2012","journal-title":"Chin. J. Biol."},{"key":"ref_237","first-page":"58","article-title":"Development of a conjugated immunogen of Pseudomonas aeruginosa lipopolysaccharide and tetanus toxoid","volume":"17","author":"Gavinho","year":"2012","journal-title":"Arch. Vet. Sci."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"e17712","DOI":"10.5812\/jjm.8(5)2015.17712","article-title":"Pseudomonas aeruginosa PAO-1 Lipopolysaccharide-Diphtheria Toxoid Conjugate Vaccine: Preparation, Characterization and Immunogenicity","volume":"8","author":"Najafzadeh","year":"2015","journal-title":"Jundishapur J. Microbiol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1128\/jcm.18.2.276-282.1983","article-title":"Detection of antibodies to Pseudomonas aeruginosa alginate extracellular polysaccharide in animals and cystic fibrosis patients by enzyme-linked immunosorbent assay","volume":"18","author":"Bryan","year":"1983","journal-title":"J. Clin. Microbiol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/infdis\/147.3.494","article-title":"Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa","volume":"147","author":"Pier","year":"1983","journal-title":"J. Infect. Dis."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1203\/00006450-198405000-00008","article-title":"Antibody to Pseudomonas aeruginosa mucoid exopolysaccharide and to sodium alginate in cystic fibrosis serum","volume":"18","author":"Speert","year":"1984","journal-title":"Pediatr. Res."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/jcm.27.4.691-699.1989","article-title":"Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis","volume":"27","author":"Pedersen","year":"1989","journal-title":"J. Clin. Microbiol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/iai.49.2.281-285.1985","article-title":"Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide","volume":"49","author":"Ames","year":"1985","journal-title":"Infect. Immun."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM198709243171303","article-title":"Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis","volume":"317","author":"Pier","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/iai.58.6.1835-1842.1990","article-title":"Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide","volume":"58","author":"Garner","year":"1990","journal-title":"Infect. Immun."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1128\/IAI.69.3.1895-1901.2001","article-title":"Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis","volume":"69","author":"Pier","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1099\/jmm.0.46696-0","article-title":"Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate","volume":"55","author":"Kashef","year":"2006","journal-title":"J. Med. Microbiol."},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Farjaha, A., Owlia, P., Siadat, S.D., Mousavi, S.F., and Shafieeardestani, M. (2014). Conjugation of alginate to a synthetic peptide containing T- and B-cell epitopes as an induction for protective immunity against Pseudomonas aeruginosa. J. Biotechnol., 192.","DOI":"10.1016\/j.jbiotec.2014.10.025"},{"key":"ref_249","first-page":"317","article-title":"Immunogenicity comparison of conjugate vaccines composed of alginate and lipopolysaccharide of Pseudomonas aeruginosa bound to diphtheria toxoid","volume":"6","author":"Najafzadeh","year":"2014","journal-title":"Iran. J. Microbiol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/apm.12337","article-title":"Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa","volume":"123","author":"Farjah","year":"2015","journal-title":"APMIS"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"045016","DOI":"10.1088\/2057-1976\/aabfac","article-title":"Synthesis and immunological evaluation of a nanovaccine based on PLGA nanoparticles and alginate antigen against infections caused by Pseudomonas aeruginosa","volume":"4","author":"Alikhani","year":"2018","journal-title":"Biomed. Phys. Eng. Express"},{"key":"ref_252","first-page":"165","article-title":"Antibodies raised against N\u2032-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection","volume":"16","author":"Neville","year":"2005","journal-title":"Int. J. Mol. Med."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.vaccine.2016.01.041","article-title":"Induction of humoral immune response against Pseudomonas aeruginosa flagellin(1-161) using gold nanoparticles as an adjuvant","volume":"34","author":"Dakterzada","year":"2016","journal-title":"Vaccine"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/iai.62.2.371-376.1994","article-title":"Differentiation of Pseudomonas aeruginosa pili based on sequence and B-cell epitope analyses","volume":"62","author":"Castric","year":"1994","journal-title":"Infect. Immun."},{"key":"ref_255","first-page":"141","article-title":"Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein","volume":"1","author":"Sheth","year":"1995","journal-title":"Biomed. Pept. Proteins Nucleic Acids"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1365-2958.1994.tb00348.x","article-title":"The binding of Pseudomonas aeruginosa pili to glycosphingolipids is a tip-associated event involving the C-terminal region of the structural pilin subunit","volume":"11","author":"Lee","year":"1994","journal-title":"Mol. Microbiol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1006\/jmbi.2000.3801","article-title":"Crystal structure of Pseudomonas aeruginosa PAK pilin suggests a main-chain-dominated mode of receptor binding","volume":"299","author":"Hazes","year":"2000","journal-title":"J. Mol. Biol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"24186","DOI":"10.1074\/jbc.M100659200","article-title":"Structure of a pilin monomer from Pseudomonas aeruginosa: Implications for the assembly of pili","volume":"276","author":"Keizer","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"11427","DOI":"10.1021\/bi048957s","article-title":"Crystallographic analysis of the Pseudomonas aeruginosa strain K122-4 monomeric pilin reveals a conserved receptor-binding architecture","volume":"43","author":"Audette","year":"2004","journal-title":"Biochemistry"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1099\/mic.0.26822-0","article-title":"Significant differences in type IV pilin allele distribution among Pseudomonas aeruginosa isolates from cystic fibrosis (CF) versus non-CF patients","volume":"150","author":"Kus","year":"2004","journal-title":"Microbiology"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/jmbi.1996.0871","article-title":"Interaction of the receptor binding domains of Pseudomonas aeruginosa pili strains PAK, PAO, KB7 and P1 to a cross-reactive antibody and receptor analog: Implications for synthetic vaccine design","volume":"267","author":"Campbell","year":"1997","journal-title":"J. Mol. Biol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1747-0285.2009.00825.x","article-title":"Advantages of a synthetic peptide immunogen over a protein immunogen in the development of an anti-pilus vaccine for Pseudomonas aeruginosa","volume":"74","author":"Kao","year":"2009","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1747-0285.2010.01021.x","article-title":"Synthetic peptide vaccine development: Designing dual epitopes into a single pilin peptide immunogen generates antibody cross-reactivity between two strains of Pseudomonas aeruginosa","volume":"76","author":"Hackbarth","year":"2010","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_264","first-page":"458","article-title":"Construction, expression, purification and characterization of secretin domain of PilQ and triple PilA-related disulfide loop peptides fusion protein from Pseudomonas aeruginosa","volume":"20","author":"Faezi","year":"2017","journal-title":"Iran. J. Basic Med. Sci."},{"key":"ref_265","first-page":"34","article-title":"Molecular characterization and functional analysis of the PilQ380-706: A novel secretin domain in Pseudomonas aeruginosa","volume":"10","author":"Faezi","year":"2018","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1128\/iai.33.2.527-532.1981","article-title":"Antibodies to cell envelope proteins of Pseudomonas aeruginosa in cystic fibrosis patients","volume":"33","author":"Fernandes","year":"1981","journal-title":"Infect. Immun."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/infdis\/146.6.770","article-title":"Outer membrane proteins of Pseudomonas aeruginosa serotype strains","volume":"146","author":"Mutharia","year":"1982","journal-title":"J. Infect. Dis."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1128\/iai.42.3.1027-1033.1983","article-title":"Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies","volume":"42","author":"Mutharia","year":"1983","journal-title":"Infect. Immun."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1128\/iai.44.1.49-54.1984","article-title":"Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice","volume":"44","author":"Gilleland","year":"1984","journal-title":"Infect. Immun."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/BF01647755","article-title":"Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection","volume":"15","author":"Strigl","year":"1987","journal-title":"Infection"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/infdis\/155.6.1282","article-title":"Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model","volume":"155","author":"Gilleland","year":"1987","journal-title":"J. Infect. Dis."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/iai.56.5.1017-1022.1988","article-title":"Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model","volume":"56","author":"Gilleland","year":"1988","journal-title":"Infect. Immun."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1378\/chest.105.5.1545","article-title":"Preservation of pulmonary function by an outer membrane protein F vaccine. A study in rats with chronic pulmonary infection caused by Pseudomonas aeruginosa","volume":"105","author":"Fox","year":"1994","journal-title":"Chest"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1128\/iai.60.9.3497-3503.1992","article-title":"Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa","volume":"60","author":"Hughes","year":"1992","journal-title":"Infect. Immun."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2003.11.029","article-title":"Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections","volume":"22","author":"Baumann","year":"2004","journal-title":"Vaccine"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0928-8244(03)00094-4","article-title":"Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: Comparison of a systemic vs. a mucosal booster schedule","volume":"37","author":"Baumann","year":"2003","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1016\/j.vaccine.2009.03.010","article-title":"Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease","volume":"27","author":"Sorichter","year":"2009","journal-title":"Vaccine"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1128\/IAI.66.8.3990-3994.1998","article-title":"A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection","volume":"66","author":"Staczek","year":"1998","journal-title":"Infect. Immun."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1099\/13500872-145-1-211","article-title":"Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus","volume":"145","author":"Brennan","year":"1999","journal-title":"Microbiology"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1574-695X.2000.tb01442.x","article-title":"Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection","volume":"27","author":"Gilleland","year":"2000","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/S0264-410X(99)00571-X","article-title":"Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa","volume":"18","author":"Staczek","year":"2000","journal-title":"Vaccine"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1172\/JCI23135","article-title":"Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid","volume":"115","author":"Worgall","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"13801","DOI":"10.1128\/JVI.01246-07","article-title":"Protective immunity to Pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF","volume":"81","author":"Worgall","year":"2007","journal-title":"J. Virol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.vaccine.2010.12.087","article-title":"Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF","volume":"29","author":"Krause","year":"2011","journal-title":"Vaccine"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1016\/j.vaccine.2017.10.078","article-title":"Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection","volume":"35","author":"Gomi","year":"2017","journal-title":"Vaccine"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1128\/JCM.02182-08","article-title":"Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis","volume":"47","author":"Rao","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4161\/hv.23226","article-title":"Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection","volume":"9","author":"Moore","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3724\/SP.J.1008.2015.01092","article-title":"Prokaryotic expression, polyclonal antibody preparation and immunoprotection potential of Pseudomonas aeruginosa outer membrane protein OprH","volume":"36","author":"Liu","year":"2015","journal-title":"Acad. J. Second Mil. Med. Univ."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1128\/IAI.69.9.5908-5910.2001","article-title":"PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice","volume":"69","author":"Holder","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/iai.16.1.362-366.1977","article-title":"Incidence of exotoxin production by Pseudomonas species","volume":"16","author":"Bjorn","year":"1977","journal-title":"Infect. Immun."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1128\/iai.15.3.776-780.1977","article-title":"Exotoxin production by clinical isolates of Pseudomonas aeruginosa","volume":"15","author":"Pollack","year":"1977","journal-title":"Infect. Immun."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1172\/JCI109300","article-title":"Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man","volume":"63","author":"Pollack","year":"1979","journal-title":"J. Clin. Investig."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/infdis\/142.4.538","article-title":"Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans","volume":"142","author":"Cross","year":"1980","journal-title":"J. Infect. Dis."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/iai.25.3.828-830.1979","article-title":"Evaluation of Pseudomonas aeruginosa toxin A in experimental rat burn wound sepsis","volume":"25","author":"Walker","year":"1979","journal-title":"Infect. Immun."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/iai.32.2.759-768.1981","article-title":"Effect of formalin toxoiding on Pseudomonas aeruginosa toxin A: Biological, chemical, and immunochemical studies","volume":"32","author":"Cryz","year":"1981","journal-title":"Infect. Immun."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1128\/iai.32.2.681-689.1981","article-title":"Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids","volume":"32","author":"Pavlovskis","year":"1981","journal-title":"Infect. Immun."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/infdis\/145.2.688","article-title":"Toxoid from exotoxin A of Pseudomonas aeruginosa: Preparation and characterization","volume":"145","author":"Pollack","year":"1982","journal-title":"J. Infect. Dis."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1073\/pnas.80.10.2870","article-title":"Pseudomonas exotoxin A: Toxoid preparation by photoaffinity inactivation","volume":"80","author":"Marburg","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"S992","DOI":"10.1093\/clinids\/5.Supplement_5.S992","article-title":"Toxoids of Pseudomonas aeruginosa toxin A: Production by chemical and genetic means","volume":"5","author":"Cryz","year":"1983","journal-title":"Rev. Infect. Dis."},{"key":"ref_300","doi-asserted-by":"crossref","unstructured":"Manafi, A., Kohanteb, J., Mehrabani, D., Japoni, A., Amini, M., Naghmachi, M., Zaghi, A.H., and Khalili, N. (2009). Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model. BMC Microbiol., 9.","DOI":"10.1186\/1471-2180-9-23"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1292\/jvms1939.44.289","article-title":"Effects of immunization of horses with common antigen (OEP), protease toxoid, and elastase toxoid on corneal ulceration due to Pseudomonas aeruginosa infection","volume":"44","author":"Ueda","year":"1982","journal-title":"Jpn. J. Vet. Sci."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"S858","DOI":"10.1093\/clinids\/5.Supplement_5.S858","article-title":"Effectiveness of immunization with multicomponent vaccines in protection against hemorrhagic pneumonia due to Pseudomonas aeruginosa infection in mink","volume":"5","author":"Homma","year":"1983","journal-title":"Rev. Infect. Dis."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1099\/00222615-47-4-303","article-title":"Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice","volume":"47","author":"Matsumoto","year":"1998","journal-title":"J. Med. Microbiol."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000414347","article-title":"A multicomponent Pseudomonas aeruginosa vaccine consisting of toxoids of protease, elastase, exotoxin A and a common protective antigen (OEP). Application in patients with diffuse panbronchiolitis","volume":"39","author":"Homma","year":"1987","journal-title":"Antibiot. Chemother. (1971)"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eimc.2010.05.006","article-title":"Polimorfismo de los genes mucA y fpvA en Pseudomonas aeruginosa de pacientes con fibrosis qu\u00edstica: Coexistencia de variantes gen\u00e9ticas en el mismo paciente","volume":"29","author":"Pozuelo","year":"2011","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1021\/ja0578698","article-title":"Antibody interference with N-acyl homoserine lactone-mediated bacterial quorum sensing","volume":"128","author":"Kaufmann","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/iai.57.1.235-238.1989","article-title":"Effect of oral immunization with Pseudomonas aeruginosa on the development of specific antibacterial immunity in the lungs","volume":"57","author":"Freihorst","year":"1989","journal-title":"Infect. Immun."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1128\/IAI.74.2.975-983.2006","article-title":"A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection","volume":"74","author":"Zaidi","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4161\/hv.7.10.16369","article-title":"Recent developments for Pseudomonas vaccines","volume":"7","author":"Sharma","year":"2011","journal-title":"Hum. Vaccines"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1574-695X.2000.tb01425.x","article-title":"Analysis of immunization with DNA encoding Pseudomonas aeruginosa exotoxin A","volume":"27","author":"Galloway","year":"2000","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0264-410X(00)00335-2","article-title":"Mice immunized with DNA encoding a modified Pseudomonas aeruginosa exotoxin A develop protective immunity against exotoxin intoxication","volume":"19","author":"Shiau","year":"2000","journal-title":"Vaccine"},{"key":"ref_312","doi-asserted-by":"crossref","unstructured":"Jiang, M., Yao, J., and Feng, G. (2014). Protective effect of DNA vaccine encoding Pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096609"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1080\/21645515.2016.1219003","article-title":"Vaccine adjuvants: Why and how","volume":"12","author":"Christensen","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/14760584.2019.1604231","article-title":"Selection of adjuvants for vaccines targeting specific pathogens","volume":"18","author":"Sarkar","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_316","first-page":"1459394","article-title":"Adjuvants: Classification, Modus Operandi, and Licensing","volume":"2016","author":"Lunardelli","year":"2016","journal-title":"J. Immunol. Res."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.phrs.2015.08.003","article-title":"Vaccines, adjuvants and autoimmunity","volume":"100","author":"Baker","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: What you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.imbio.2010.10.005","article-title":"Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella Typhimurium infection","volume":"216","author":"Jazani","year":"2011","journal-title":"Immunobiology"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"3713656","DOI":"10.1155\/2016\/3713656","article-title":"A de-O-acylated Lipooligosaccharide-Based Adjuvant System Promotes Antibody and Th1-Type Immune Responses to H1N1 Pandemic Influenza Vaccine in Mice","volume":"2016","author":"Ryu","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.4014\/jmb.1706.06009","article-title":"Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System","volume":"27","author":"Ryu","year":"2017","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00011-020-01377-3","article-title":"SARS-CoV-2 will constantly sweep its tracks: A vaccine containing CpG motifs in \u2018lasso\u2019 for the multi-faced virus","volume":"69","author":"Oberemok","year":"2020","journal-title":"Inflamm. Res."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Rappuoli","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"104079","DOI":"10.1016\/j.cellimm.2020.104079","article-title":"Curdlan stimulates tissue mast cells to synthesize pro-inflammatory mediators, generate ROS, and migrate via Dectin-1 receptor","volume":"351","author":"Wiktorska","year":"2020","journal-title":"Cell. Immunol."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-065X.2009.00793.x","article-title":"Beta-glucan recognition by the innate immune system","volume":"230","author":"Goodridge","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_328","doi-asserted-by":"crossref","unstructured":"Clements, J.D., and Norton, E.B. (2018). The Mucosal Vaccine Adjuvant LT(R192G\/L211A) or dmLT. mSphere, 3.","DOI":"10.1128\/mSphere.00215-18"},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2147\/DDDT.S189847","article-title":"Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa","volume":"13","author":"Hoggarth","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0264-410X(94)90246-1","article-title":"Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella dublin","volume":"12","author":"Toth","year":"1994","journal-title":"Vaccine"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1128\/IAI.72.11.6546-6553.2004","article-title":"Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa","volume":"72","author":"Arnold","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.vaccine.2009.10.080","article-title":"Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers","volume":"28","author":"Bumann","year":"2010","journal-title":"Vaccine"},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/1348-0421.12291","article-title":"Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa","volume":"59","author":"Zhang","year":"2015","journal-title":"Microbiol. Immunol."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"e00116-19","DOI":"10.1128\/mSphere.00116-19","article-title":"A Live Salmonella Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa","volume":"4","author":"McConnell","year":"2019","journal-title":"mSphere"},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1128\/iai.63.8.2818-2825.1995","article-title":"Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies","volume":"63","author":"Pier","year":"1995","journal-title":"Infect. Immun."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1128\/IAI.72.12.7012-7021.2004","article-title":"Oral vaccination of BALB\/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model","volume":"72","author":"DiGiandomenico","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1073\/pnas.0608657104","article-title":"Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections","volume":"104","author":"DiGiandomenico","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijmm.2016.06.005","article-title":"Heterologous Pseudomonas aeruginosa O-antigen delivery using a Salmonella enterica serovar Typhimurium wecA mutant strain","volume":"306","author":"Bridge","year":"2016","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/21655979.2015.1011033","article-title":"Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections","volume":"6","author":"Robinson","year":"2015","journal-title":"Bioengineered"},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0278-6915(99)00013-7","article-title":"A toxicological assessment of Curdlan","volume":"37","author":"Spicer","year":"1999","journal-title":"Food Chem. Toxicol."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jconrel.2020.01.028","article-title":"Polyester based polymeric nano and microparticles for pharmaceutical purposes: A review on formulation approaches","volume":"320","author":"Molavi","year":"2020","journal-title":"J. Control Release"},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fcimb.2018.00154","article-title":"Live attenuated tularemia vaccines for protection against respiratory challenge with virulent F. tularensis subsp. tularensis","volume":"8","author":"Jia","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/ciaa585","article-title":"Assessing the Feasibility of Typhoid Elimination","volume":"71","author":"Stanaway","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/cei.13285","article-title":"Mucosal vaccines and technology","volume":"196","author":"Bentley","year":"2019","journal-title":"Clin. Exp. Immunol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/12\/2617\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:41:29Z","timestamp":1760179289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/12\/2617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,5]]},"references-count":344,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["cells9122617"],"URL":"https:\/\/doi.org\/10.3390\/cells9122617","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,5]]}}}